The group therapy hypothesis suggests that group sessions enhance social connectedness and well-being by fostering communitas, psychological safety, empathy, cooperation, and aiding in psychological integration and self-regulation. Despite much observation of the effectiveness of group healing practices rooted in non-Western and ancient cultures, these methods have not been widely adopted in Western therapy.
ATMA, in partnership with experts like Dr. Simon Ruffell and Carlos Tanner is working towards clinical trials using a group administration protocol. This initiative aims to improve accessibility in the challenging landscape of psychedelic therapy due to resource constraints.
Join ATMA, Dr. Simon Ruffell and Carlos Tanner for a discussion on the efficacy and accessibility of group psychedelic therapy. Dr. Ruffell, with a background in psychiatry, research psychology, and traditional plant medicine practices, offers unique insights from leading clinical trials, including psilocybin for treatment-resistant depression.
Carlos Tanner has been studying the science of ayahuasca and plant medicine in the Amazon Rainforest since 2003. He currently works as the director of the Ayahuasca Foundation, a non-profit organization he began in 2009 in Iquitos, Peru
Don’t miss this chance to explore the benefits of group psychedelic therapy and learn about our upcoming clinical trial starting in late summer.